Effects of 4-methylcatechol, a stimulator of endogenous nerve growth factor synthesis, on experimental acrylamide-induced neuropathy in rats.

Paper

Effects of 4-methylcatechol, a stimulator of endogenous nerve growth factor synthesis, on experimental acrylamide-induced neuropathy in rats.

Published Jun 30, 1996 · K. Saita, T. Ohi, Y. Hanaoka

Neurotoxicology

Q2 SJR score

22

Citations

0

Influential Citations

Semantic Scholar

Abstract

Acrylamide monomer (ACR) causes central-peripheral distal axonopathy. We induced neuropathy in rats by means of ACR injection as an experimental model of the dying-back type of peripheral neuropathy to assess the potential efficacy of 4-methylcatechol (4-MC), a potent stimulator of endogenous nerve growth factor (NGF) synthesis, as a therapeutic agent for the axonal nerve lesion. ACR-induced neuropathy in rats resulted in a dying- back type of axonal degeneration, and a statistically significant reduction in motor nerve conduction velocity (MNCV), and density of large myelinated fibers. We administered 4-MC and ACR together to rats intraperitoneally and found improved clinical signs, and significantly more NGF content in sciatic nerves, faster MNCV, and greater myelinated fiber density than in rats given ACR alone. These findings suggest that 4-MC can prevent the progression of ACR-induced neuropathy and decreased NGF levels may be involved in the pathogenesis of ACR neuropathy.

Non-RCT

Animal Study

Study Snapshot

4-methylcatechol, a stimulator of nerve growth factor synthesis, can prevent the progression of acrylamide-induced neuropathy in rats, suggesting decreased NGF levels may play a role in its pathogenesis.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Effects of 4-methylcatechol, a stimulator of endogenous nerve growth factor synthesis, on experimental acrylamide-induced neuropathy in rats.

Sign up to use Study Snapshot

References

Citations

Distinct TrkA and Ret modulated negative and positive neuropathic behaviors in a mouse model of resiniferatoxin-induced small fiber neuropathy

Distinct neurotrophic factor receptors, TrkA and Ret, account for negative and positive neuropathic behaviors in resiniferatoxin-induced small fiber neuropathy, respectively.

Nerve Sprouting Contributes to Increased Severity of Ventricular Tachyarrhythmias by Upregulating iGluRs in Rats with Healed Myocardial Necrotic Injury

Sympathetic nerve sprouting in healed myocardial infarction increases the severity of ventricular tachyarrhythmias by upregulating ionotropic glutamate receptors.

Nerve sprouting suppresses myocardial I to and I K1 channels and increases severity to ventricular fibrillation in rat

Nerve sprouting in rats increases the susceptibility to ventricular fibrillation by suppressing myocardial I to and I K1 channels and reducing phosphorylation of ERK and CREB.

Spinal α2 Adrenoceptor and Antiallodynic Effect by Clonidine after Chronic Administration of 4-Methylcatechol in Neuropathic Rat Pain Model

Chronic intraperitoneal administration of 4-methylcatechol may improve the anti-neuropathic pain effect of intrathecal clonidine, but does not increase spinal 2A and 2C adrenoceptors.

Protection of sensory function in diabetic rats by Neotrofin.

Neotrofin treatment, which enhances endogenous nerve growth factor levels, may be an alternative therapeutic approach for treating diabetic neuropathy.

Cisplatin-induced peripheral neurotoxicity in rats reduces the circulating levels of nerve growth factor

Cisplatin-induced peripheral neurotoxicity in rats reduces circulating levels of nerve growth factor, suggesting a specific role for NGF in primary sensory neuron damage.

Continuous delivery of neurotrophin 3 by gene therapy has a neuroprotective effect in experimental models of diabetic and acrylamide neuropathies.

Continuous delivery of neurotrophin 3 by adenovirus-based gene therapy shows potential in preventing early diabetic neuropathy and axonal neuropathies, with minimal muscle inflammation and no detectable general side effects.